

Oncothermia in practice: quality assurance, applications, devices

Balazs Acs¹, Oliver Szasz²

(1) Oncotherm Kft. 2071-Paty, Ibolya u. 2., Hungary

(2) Department of Biotechnics, Szent Istvan University, 2100-Godollo, Pater K. u. 1.

Corresponding author: acsbalazs@oncotherm.org

Oncothermia in practice: quality assurance, applications, devices

Introduction

Various kinds of hyperthermia devices are used in oncology, but the stable breakthrough of the applications has not been reached yet. Oncothermia offers strong scientific basis and good clinical practice as well. The very dynamic scientific and medical activity of Oncotherm is known in the scientific community through its many publications and accepted results. We are pioneering the electromagnetic treatments in oncology. The modulated electric field with RF carrier frequency of oncothermia is a leading method in oncologic hyperthermia by its treatment number all over the world. We are very active at all the international forums and conferences to make conditions risk-free and safe, ensure the patients of the safety of the treatment and your business also. The objective of this work is to show the oncothermia in practice and make sure the information about the actual safety regulations and certifications.

Method

Oncotherm is seriously concerned about the legal protection of its customers. All devices have market approvals (CE according to European Medical Device Directive) and the production has the well-known rigorous standards (ISO13485, ISO9001). For better services for suffering patients we are offering various specialized devices for special treatments like intraluminal (EHY1000 series) (mainly for prostate), loco-regional (EHY2000 series) and multilocal (EHY3000 series) equipments. We are more than happy to show the very new devices as the Androtherm for Peyronie diseases, the Booster, the special temperature measurement and the very new member of the Oncotherm devices: the new ECT series. According to the general information request, we have shown how the devices work, and answered the practitioners' questions. We have also shown some experiments to see how the devices work and which effects can penetrate deeply in the body at the treatments of various organs.

Results

Oncothermia follows the update demands of the modern oncology:

- It is personalized therapy,
- It is non toxic,
- It elongates the survival time of the patients,
- It completes the curative actions with increased quality of life,
- It has good cost/benefit ratio.

The introduced new paradigm by oncothermia solved the classical challenges:

- Challenge (1): "The biology is with us while the physics is against us" [1]
✓ *Oncothermia solution*: "The biophysics is with us"
- Challenge (2): "The biology and the physics are with us while the physiology is against us" [2]
✓ *Oncothermia solution*: "The fractal physiology is with us"
- Challenge (3): "Reference point is needed!" [3]
✓ *Oncothermia solution*: "Back to the gold standards, use the energy instead of temperature"

The task for future are challenging, and we are expecting professionals repeat our results and coming with us to fight in the war against cancer [4].

Conclusion

Oncothermia selects the malignant cells and acts differently from the physiological homeostatic reactions (heat-flow on the membrane supported by the electric field effects). It is natural, it is not against the homeostasis, physiology does not work against the action. Numerous case reports show the effect of Oncothermia well, so it has become a good weaponry in the war of cancer.

References

- [1] Overgaard J, Nielsen OS, Lindegaard JC (1987) Biological basis for rational design of clinical treatment with combined hyperthermia and radiation. In: Physics and Technology of Hyperthermia, Field SB, Franconi C, (Eds.) NATO ASI Series, E: Applied Sciences, No. 127. Martinus Nijhoff Publ. Dordrecht/Boston, pp. 54-79.
- [2] Osinsky S, Ganul V, Protsyk V et al (2004) Local and regional hyperthermia in combined treatment of malignant tumors: 20 years experience in Ukraine, The Kadota Fund International Forum 2004, Awaji Japan, Jun 15-18
- [3] Fatehi D, van der Zee J, van der Wal E et al (2006) Temperature data analysis for 22 patients with advanced cervical carcinoma treated in Rotterdam using radiotherapy, hyperthermia and chemotherapy: a reference point is needed. *Int J Hyperthermia* 22:353-363
- [4] US National Cancer Act of 1971 signed by then U.S. President Richard Nixon.